SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging
vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS …

In recent months, additional Omicron variants of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), including the BA. 5 sublineage BF. 7 and BQ. 1.1 and the BA …

The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically …

The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …

Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures.
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …

Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …

Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Neutralizing monoclonal antibodies (nAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) represent promising candidates for clinical intervention against …

The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies
worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike is the target for
neutralizing antibodies elicited following both infection and vaccination. While extensive …